← Back to Screener
Liminatus Pharma, Inc. Warrants (LIMNW)
Price$0.09
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-55.84%
Price vs S&P 500 (4W)52.66%
VGM Score71.43
All Metrics
Price vs S&P 500 (YTD)147.06%
10-Day Avg Trading Volume0.02M
3-Month Avg Trading Volume0.02M
52-Week High$0.47
26-Week Price Return-44.10%
13-Week Price Return126.70%
3-Month Return Std Dev586.65%
Year-to-Date Return157.14%
5-Day Price Return0.00%
Month-to-Date Return-6.93%
Price vs S&P 500 (13W)115.84%
Beta0.55x
52-Week Low$0.03
mGradeB
vgmGradeB
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LIMNWLiminatus Pharma, Inc. Warrants | — | — | B | $0.09 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy in Phase II trials targeting colorectal, pancreatic, gastric, and esophageal cancers expressing Guanylyl Cyclase C. The vaccine is designed to stimulate immune responses against these gastrointestinal malignancies.